Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology
NIH launches Accelerating Medicines Partnership for schizophrenia
NIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative to find biomarkers that identify individuals at risk for developing schizophrenia, predict the likelihood of disease progression and point to therapeutic targets. Companies involved include Boehringer Ingelheim GmbH, Otsuka Holdings Co. Ltd. (Tokyo:4578) and the Janssen Research & Development unit of Johnson & Johnson (NYSE:JNJ). External partners will contribute $16.5 million over five years, and NIH’s National Institute of Mental Health (NIMH) plans to contribute $82.5 million over the same period. AMP SCZ is NIH’s fifth AMP initiative, and the first focused on a neurological disease.
Boehringer, Click partner for digital therapeutic for schizophrenia
Boehringer and Click Therapeutics Inc. are partnering to develop and commercialize CT-155, a prescription-based mobile application based on the principles of cognitive behavioral therapy. The German pharma will receive exclusive global rights to CT-155; Click will receive an undisclosed upfront payment and development funding, and is eligible to receive clinical, regulatory and commercial milestones for a total deal value of more than $500 million, plus tiered royalties...